Clinical significance of serum oxidized low-density lipoprotein/ β2-glycoprotein I complexes in patients with chronic renal diseases

Junko Kasahara, Kazuko Kobayashi, Yohei Maeshima, Yasushi Yamasaki, Tatsuji Yasuda, Eiji Matsuura, Hirofumi Makino

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Peroxidation of low-density lipoprotein (LDL) plays an important role in the development of dyslipidemias associated with the progression of chronic renal disorders. We recently reported [J Lipid Res 2001;42:697, 2002;43:1486, 2003;44:716] that oxidized LDL (oxLDL) interacts with an endogenous plasma protein, β2-glycoprotein I (β2GPI), via specific ligands. In the present study, the prevalence and clinical significance of oxLDL/β2GPI complexes were evaluated in patients with chronic renal disorders. Methods: Serum levels of oxLDL/β2GPI complexes were measured by ELISA in patients with chronic renal disease and their association with clinical manifestations was assessed. Results: The serum levels of oxLDL/β2GPI complexes were significantly higher in patients with chronic renal failure (CRF), chronic nephritis (CN) and diabetes mellitus than those in healthy individuals. The presence of complexes in patients with CN was significantly associated with high dietary protein and sodium chloride intake, but not with lipid metabolic parameters. Malondialdehyde-modified LDL was significantly associated with total cholesterol and LDL cholesterol in all patient groups, but did not correlate with renal function parameters. Conclusions: Serum oxLDL/β2GPI complexes, generated by oxidative stress and associated with high dietary protein and salt intake, might be a novel risk factor and a diagnostic marker for the development of chronic renal diseases, especially IgA nephropathy.

Original languageEnglish
JournalNephron - Clinical Practice
Volume98
Issue number1
DOIs
Publication statusPublished - 2004

Fingerprint

Chronic Renal Insufficiency
LDL Lipoproteins
Glycoproteins
Serum
Dietary Proteins
Nephritis
Kidney
Dietary Sodium Chloride
Lipids
Dyslipidemias
Malondialdehyde
LDL Cholesterol
Immunoglobulin A
Chronic Kidney Failure
oxidized low density lipoprotein
Blood Proteins
Diabetes Mellitus
Oxidative Stress
Salts
Enzyme-Linked Immunosorbent Assay

Keywords

  • β-Glycoprotein I
  • Enzyme-linked immunosorbent assay
  • Kidney diseases
  • Oxidized low-density lipoprotein

ASJC Scopus subject areas

  • Nephrology

Cite this

@article{2aee604721054acbbe489ebea0fb487d,
title = "Clinical significance of serum oxidized low-density lipoprotein/ β2-glycoprotein I complexes in patients with chronic renal diseases",
abstract = "Background: Peroxidation of low-density lipoprotein (LDL) plays an important role in the development of dyslipidemias associated with the progression of chronic renal disorders. We recently reported [J Lipid Res 2001;42:697, 2002;43:1486, 2003;44:716] that oxidized LDL (oxLDL) interacts with an endogenous plasma protein, β2-glycoprotein I (β2GPI), via specific ligands. In the present study, the prevalence and clinical significance of oxLDL/β2GPI complexes were evaluated in patients with chronic renal disorders. Methods: Serum levels of oxLDL/β2GPI complexes were measured by ELISA in patients with chronic renal disease and their association with clinical manifestations was assessed. Results: The serum levels of oxLDL/β2GPI complexes were significantly higher in patients with chronic renal failure (CRF), chronic nephritis (CN) and diabetes mellitus than those in healthy individuals. The presence of complexes in patients with CN was significantly associated with high dietary protein and sodium chloride intake, but not with lipid metabolic parameters. Malondialdehyde-modified LDL was significantly associated with total cholesterol and LDL cholesterol in all patient groups, but did not correlate with renal function parameters. Conclusions: Serum oxLDL/β2GPI complexes, generated by oxidative stress and associated with high dietary protein and salt intake, might be a novel risk factor and a diagnostic marker for the development of chronic renal diseases, especially IgA nephropathy.",
keywords = "β-Glycoprotein I, Enzyme-linked immunosorbent assay, Kidney diseases, Oxidized low-density lipoprotein",
author = "Junko Kasahara and Kazuko Kobayashi and Yohei Maeshima and Yasushi Yamasaki and Tatsuji Yasuda and Eiji Matsuura and Hirofumi Makino",
year = "2004",
doi = "10.1159/000079923",
language = "English",
volume = "98",
journal = "Experimental Nephrology",
issn = "0028-2766",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Clinical significance of serum oxidized low-density lipoprotein/ β2-glycoprotein I complexes in patients with chronic renal diseases

AU - Kasahara, Junko

AU - Kobayashi, Kazuko

AU - Maeshima, Yohei

AU - Yamasaki, Yasushi

AU - Yasuda, Tatsuji

AU - Matsuura, Eiji

AU - Makino, Hirofumi

PY - 2004

Y1 - 2004

N2 - Background: Peroxidation of low-density lipoprotein (LDL) plays an important role in the development of dyslipidemias associated with the progression of chronic renal disorders. We recently reported [J Lipid Res 2001;42:697, 2002;43:1486, 2003;44:716] that oxidized LDL (oxLDL) interacts with an endogenous plasma protein, β2-glycoprotein I (β2GPI), via specific ligands. In the present study, the prevalence and clinical significance of oxLDL/β2GPI complexes were evaluated in patients with chronic renal disorders. Methods: Serum levels of oxLDL/β2GPI complexes were measured by ELISA in patients with chronic renal disease and their association with clinical manifestations was assessed. Results: The serum levels of oxLDL/β2GPI complexes were significantly higher in patients with chronic renal failure (CRF), chronic nephritis (CN) and diabetes mellitus than those in healthy individuals. The presence of complexes in patients with CN was significantly associated with high dietary protein and sodium chloride intake, but not with lipid metabolic parameters. Malondialdehyde-modified LDL was significantly associated with total cholesterol and LDL cholesterol in all patient groups, but did not correlate with renal function parameters. Conclusions: Serum oxLDL/β2GPI complexes, generated by oxidative stress and associated with high dietary protein and salt intake, might be a novel risk factor and a diagnostic marker for the development of chronic renal diseases, especially IgA nephropathy.

AB - Background: Peroxidation of low-density lipoprotein (LDL) plays an important role in the development of dyslipidemias associated with the progression of chronic renal disorders. We recently reported [J Lipid Res 2001;42:697, 2002;43:1486, 2003;44:716] that oxidized LDL (oxLDL) interacts with an endogenous plasma protein, β2-glycoprotein I (β2GPI), via specific ligands. In the present study, the prevalence and clinical significance of oxLDL/β2GPI complexes were evaluated in patients with chronic renal disorders. Methods: Serum levels of oxLDL/β2GPI complexes were measured by ELISA in patients with chronic renal disease and their association with clinical manifestations was assessed. Results: The serum levels of oxLDL/β2GPI complexes were significantly higher in patients with chronic renal failure (CRF), chronic nephritis (CN) and diabetes mellitus than those in healthy individuals. The presence of complexes in patients with CN was significantly associated with high dietary protein and sodium chloride intake, but not with lipid metabolic parameters. Malondialdehyde-modified LDL was significantly associated with total cholesterol and LDL cholesterol in all patient groups, but did not correlate with renal function parameters. Conclusions: Serum oxLDL/β2GPI complexes, generated by oxidative stress and associated with high dietary protein and salt intake, might be a novel risk factor and a diagnostic marker for the development of chronic renal diseases, especially IgA nephropathy.

KW - β-Glycoprotein I

KW - Enzyme-linked immunosorbent assay

KW - Kidney diseases

KW - Oxidized low-density lipoprotein

UR - http://www.scopus.com/inward/record.url?scp=4644264529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644264529&partnerID=8YFLogxK

U2 - 10.1159/000079923

DO - 10.1159/000079923

M3 - Article

C2 - 15361700

AN - SCOPUS:4644264529

VL - 98

JO - Experimental Nephrology

JF - Experimental Nephrology

SN - 0028-2766

IS - 1

ER -